Daxas REMS May Be Key To Approval After "Complete Response" Letter

FDA seems more likely to approve the COPD if labeling is restricted to moderate-to-severe patients with chronic bronchitis, but Forest will probably need to show that it can limit use.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet